Is IL-4 a potential therapeutic target in systemic sclerosis-associated pulmonary fibrosis?

Clinical Immunology

Volumn 141, Issue 3, 2011, Pages 240-241

  Sfikakis, Petros P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; INTERLEUKIN 4; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; EDITORIAL; FIBROBLAST; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; INTERLEUKIN-4; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SCLERODERMA, SYSTEMIC;

EID: 81355148642     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.09.010     Document Type: Editorial

References (10)

1. Spiera R.F., Gordon J.K., Mersten J.N., Magro C.M., Mehta M., Wildman H.F., Kloiber S., Kirou K.A., Lyman S., Crow M.K. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann. Rheum. Dis. 2011, 70:1003-1009.
2. Khanna D., Saggar R., Mayes M.D., Abtin F., Clements P.J., Maranian P., Assassi S., Saggar R., Singh R.R., Furst D.E. Open-label pilot trial of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis-associated active interstitial lung disease (SSc-ILD). Arthritis Rheum. 2011, [Epub ahead of print].
3. Pope J., McBain D., Petrlich L., Watson S., Vanderhoek L., de Leon F., Seney S., Summers K. Imatinib in active diffuse systemic sclerosis: a single site trial. Arthritis Rheum. 2011, [Epub ahead of print].
4. Iwamoto N., Distler J.H., Distler O. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Curr. Rheumatol. Rep. 2011, 13:21-27.
5. + T cells in the broncho-alveolar lavage of patients with systemic sclerosis. Clin. Immunol. 2011, 141:293-303.
6. Pechkovsky D.V., Prasse A., Kollert F., Engel K.M., Dentler J., Luttmann W., Friedrich K., Müller-Quernheim J., Zissel G. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin. Immunol. 2010, 137:89-1016.
7. Yamaji-Kegan K., Su Q., Angelini D.J., Myers A.C., Cheadle C., Johns R.A. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) increases lung inflammation and activates pulmonary microvascular endothelial cells via an IL-4-dependent mechanism. J. Immunol. 2010, 185:5539-5548.
8. Lo Re S., Lecocq M., Uwambayinema F., Yakoub Y., Delos M., Demoulin J.B., Lucas S., Sparwasser T., Renauld J.C., Lison D. Huaux F PDGF-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. Am. J. Respir. Crit. Care Med. Aug 25 2011, [Epub ahead of print].
9. Liu F., Liu J., Weng D., Chen Y., Song L., He Q., Chen J. CD4+CD25+Foxp3+ regulatory T cells depletion may attenuate the development of silica-induced lung fibrosis in mice. PLoS One 2010, 5:e15404.
10. Ong C., Wong C., Roberts C.R., Teh H.S., Jirik F.R. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur. J. Immunol. 1998, 28:2619-2629.